- Home
- SUPN vs ARWR Comparison
SUPN vs ARWR Comparison
Compare SUPN & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- ARWR
- Stock Information
- Founded
- SUPN 2005
- ARWR 2003
- Country
- SUPN United States
- ARWR United States
- Employees
- SUPN N/A
- ARWR N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- ARWR Biotechnology: Pharmaceutical Preparations
- Sector
- SUPN Health Care
- ARWR Health Care
- Exchange
- SUPN Nasdaq
- ARWR Nasdaq
- Market Cap
- SUPN 1.8B
- ARWR 1.8B
- IPO Year
- SUPN 2012
- ARWR 1993
- Fundamental
- Price
- SUPN $32.46
- ARWR $18.71
- Analyst Decision
- SUPN Hold
- ARWR Buy
- Analyst Count
- SUPN 2
- ARWR 8
- Target Price
- SUPN $36.00
- ARWR $43.71
- AVG Volume (30 Days)
- SUPN 747.3K
- ARWR 1.5M
- Earning Date
- SUPN 08-05-2025
- ARWR 08-07-2025
- Dividend Yield
- SUPN N/A
- ARWR N/A
- EPS Growth
- SUPN N/A
- ARWR N/A
- EPS
- SUPN 1.11
- ARWR N/A
- Revenue
- SUPN $667,997,000.00
- ARWR $545,209,000.00
- Revenue This Year
- SUPN N/A
- ARWR $21,924.50
- Revenue Next Year
- SUPN $12.02
- ARWR N/A
- P/E Ratio
- SUPN $29.24
- ARWR N/A
- Revenue Growth
- SUPN 11.82
- ARWR 1436.97
- 52 Week Low
- SUPN $25.94
- ARWR $9.57
- 52 Week High
- SUPN $40.28
- ARWR $30.41
- Technical
- Relative Strength Index (RSI)
- SUPN 53.20
- ARWR 70.78
- Support Level
- SUPN $31.35
- ARWR $16.45
- Resistance Level
- SUPN $32.55
- ARWR $17.18
- Average True Range (ATR)
- SUPN 0.91
- ARWR 0.78
- MACD
- SUPN 0.04
- ARWR 0.17
- Stochastic Oscillator
- SUPN 60.93
- ARWR 97.06
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.